The US Association for Accessible Medicines says it is actively working to mitigate coronavirus-related disruptions on the off-patent industry’s supply chain, with contingency planning a “top priority” for generics and biosimilars firms.
AAM Working To Mitigate Coronavirus Effects
US Association Says Contingency Planning Is A ‘Top Priority’
The US Association for Accessible Medicines says it is actively working with industry stakeholders to mitigate coronavirus-related disruptions to the off-patent industry’s supply chain, with contingency planning a “top priority.”
More from Regulation
• By
Echoing wider sentiments in the biosimilar and generic drug industry, the IGBA has warned of the potential consequences of mercantilist tariffs on the global drug supply and their impact on industry and patients.
• By
Alvotech and Advanz have announced a UK MHRA filing acceptance for their partnered AVT23 proposed biosimilar to Xolair (omalizumab).
• By
As Indian CROs are bracing for new registration mandates, an expert panel at the IGBA’s 3rd Bioequivalence conference discusses the implications of non-compliance in bioequivalence studies.
• By
Complaints from UK originator association the ABPI over rising payments required by the country’s voluntary scheme for branded medicines pricing have been denounced by the BGMA, which says the differentiated scheme is “delivering precisely as it was intended.”
More from Policy & Regulation
• By
Complaints from UK originator association the ABPI over rising payments required by the country’s voluntary scheme for branded medicines pricing have been denounced by the BGMA, which says the differentiated scheme is “delivering precisely as it was intended.”
• By
The FDA generic drugs team’s first public workshop of the second Trump Administration ended with a request that industry amplify the value it finds from public engagement.
• By
Generics Bulletin reviews global regulatory developments across the globe.